|Over a quarter ago|
Poxel initiated with an Outperform at JMP Securities » 06:2406/2306/23/20
JMP Securities analyst…
JMP Securities analyst Jason Butler initiated coverage of Poxel with an Outperform rating and EUR 21 price target. The analyst cites the company's "most advanced program", imeglimin for type 2 diabetes, having completed its pivotal program in Japan, with Phase 3 trials being planned to begin in the U.S. and Europe. Butler adds that Poxel's two candidates for NASH - PXL770 and PXL650 - also represent "differentiated and compelling opportunities", anticipating their clinical readouts this year to generate "significant near-term value drivers".
Poxel initiated with an Outperform at JMP Securities » 05:3506/2306/23/20
JMP Securities initiated…
JMP Securities initiated coverage of Poxel with an Outperform rating and EUR 21 price target.